Latin America Liver Cancer Market 2019 Overview, Competitive Analysis and Development by Companies

The Latin American liver cancer market is expected to register a CAGR of nearly 7.4% during the forecast period.
Changes in the current lifestyle of individuals have led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type-2 diabetes, metabolic disorders, excess body weight, alcohol consumption, and tobacco smoking. It has also been observed that liver cancer risk increases substantially with the increase in one’s body mass index (BMI).

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/19846
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

According to the OECD Obesity Update 2017, obesity levels are particularly high in Latin American countries for example in Mexico, 32.4% of males aged 15 years and over are obese as of 2017, and nearly 39% of the population is projected to become obese by 2030.

Top Players:
The Latin American liver cancer market is consolidated with some major players controlling the major share of the market, especially in the diagnostics space. Liver cancer diagnostics are majorly dependent on high-cost diagnostic imaging modalities, such as MRI, CT, and PET scanners. There are few major players in the global market, and due to the low volume of demand in Latin American countries, the concentration of medical device manufacturers is even lower. In the Latin American therapeutic space, several niche players operate and various clinical trials are underway.

Request Discount on this report @ https://marketprognosis.com/discount-request/19846
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Scope of the Report
The scope of the Latin American liver cancer market encompasses various diagnostic modalities used in the diagnosis and imaging of liver cancer and available therapies used in the management of liver cancer. Diagnostic modalities include ultrasound scans, biopsy, endoscopy, CT scan, PET scan, and magnetic resonance imaging (MRI) scans, among others. Therapeutic categories covered in the report include targeted therapy, radiation therapy, immunotherapy, and chemotherapy.

By Cancer Type Hepatocellular Carcinoma Hold the Largest Share
Hepatocellular carcinoma is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver disease, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths, globally. It is observed that the developing countries of the Latin American region have higher incidence rates of hepatocellular carcinoma than the developed countries, due to the disparity in the major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, causing hepatocellular carcinoma in those regions. With the increase in the incidence of hepatocellular carcinoma, liver cancer therapeutics is expected to have huge demand. Hence, the rising incidence of cancer and high unmet medical needs are the major factors driving the market in the forecast period.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/19846

Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.